Summary of 2Nd QUARTER 2021:
1. Revenue: Beat the predicted Revenue.
2. Profit per Share: Beat the predicted price
per share.
3. Production: Will produce 1 billion doses
2021. Will produce 3 billion doses in 2022.
4. Sales: 2021 sold out. 2022 2/3s sold out with
prepaid contracts. 2023 contracting orders.
5. Production more coming online securing
additional Production deals worldwide.
6. Pipeline = Great results.
7. Boosters starting this fall.
8. Variants
9. Vision 2021 - 2025.
$Moderna, Inc.(MRNA)$
精彩评论